New agents and regimens for diffuse large B cell lymphoma

As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance to R-CHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang, Li, Lin-rong, Young, Ken H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734862/
https://www.ncbi.nlm.nih.gov/pubmed/33317571
http://dx.doi.org/10.1186/s13045-020-01011-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734862/
https://www.ncbi.nlm.nih.gov/pubmed/33317571
http://dx.doi.org/10.1186/s13045-020-01011-z

Ejemplares similares